Healio

Combination bupivacaine, meloxicam may reduce pain, opioid use after TKA

KOLOA, Hawaii — Results showed use of Zynrelef as part of a multimodal analgesia protocol may significantly reduce pain and opioid use after total knee arthroplasty. “Zynrelef [bupivacaine and ...
Monthly Prescribing Reference

Novel Meloxicam Formulation Reduces Postop Pain in Two Trials

A reduction in opioid usage over the entire treatment period was observed in patients treated with MR-107A-02 vs placebo. Topline data were announced from two phase 3 studies evaluating MR-107A-02 for ...
Medscape

Efficacy and Tolerability of Meloxicam, a COX-2 Preferential Nonsteroidal Anti-Inflammatory Drug

Meloxicam is an enolcarboxamide with preferential COX-2 inhibitory activity. In vitro studies with human tissues have confirmed the high affinity of meloxicam for COX-2, whereas COX-1 was inhibited ...
Medscape

CHMP Backs Bupivacaine/Meloxicam (Zynrelef) for Postop Pain

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of the fixed-dose combination of bupivacaine and meloxicam (Zynrelef) for the ...
Seeking Alpha

Viatris Announces Positive Top-Line Results from Two Pivotal Phase 3 Studies of Novel Fast-Acting Meloxicam (MR-107A-02) for the Treatment of Moderate-to-Severe Acute Pain

In Both Acute Pain Models, MR-107A-02 Demonstrated Statistically Significant and Clinically Meaningful Improvement in Pain Compared to Placebo, Significant Reduction in Opioid Usage and Superior Pain ...